Inflammatory Disease News and Research

RSS

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has received regulatory approval from the Finnish National Supervisory Authority for Welfare and Health (Valvira) to commence a Phase 1/2 safety trial for BL-7010, for the treatment of celiac disease.

4 Nov 2013

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it executed confidentiality agreements with 10 established pharmaceutical and biotechnology companies with respect to potential negotiations for the commercialization of CF101 for the treatment of autoimmune inflammatory indications.

4 Nov 2013

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

New findings from two integrated Phase 3 Janssen Research & Development, LLC (Janssen)-sponsored studies showed treatment with STELARA- (ustekinumab) resulted in significantly greater inhibition of structural damage in patients with active psoriatic arthritis compared with placebo.

29 Oct 2013

Researchers identify risk factors, protective medication for people living with lupus

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, researchers have identified three potentially modifiable risk factors and one protective medication that may improve the health of people living with lupus.

28 Oct 2013

Study: Headache is not a sign of lupus activity

Headache is common among patients with system lupus erythematosus according to new research published in Arthritis & Rheumatism, a journal of the American College of Rheumatology.

28 Oct 2013

Biomarker may predict poor pregnancy outcomes in lupus patients

Researchers at Hospital for Special Surgery in New York City have identified a biomarker that may predict poor pregnancy outcomes in lupus patients.

28 Oct 2013

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Medicaid beneficiaries with lupus are not adequately following their treatment plans, and this puts them at risk for poor health outcomes, according to research presented this week at the American College of Rheumatology Annual Meeting in San Diego. For most lupus medications, fewer than one in three beneficiaries were found to be adherent.

28 Oct 2013

Children born to mothers with lupus have twice the risk of autism spectrum disorders

According to research presented this week at the American College of Rheumatology Annual Meeting in San Diego, children born to mothers with lupus may be at twice the risk of autism spectrum disorders than those born to mothers without the disease.

28 Oct 2013

NHMRC awards over $6M for Griffith University research projects

Griffith University research projects have been awarded just over $6m in research funding by the prestigious National Health and Medical Research Council.

28 Oct 2013

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 (JAK3) inhibitor, dosed once or twice daily in people with active rheumatoid arthritis (RA) taking methotrexate

19 Oct 2013

New injection device to reduce fear and pain of injecting modern medicines

...

15 Oct 2013

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Pfizer Inc. announced today top-line results from two Phase 3 clinical trials of tofacitinib, a novel, oral Janus kinase inhibitor that is being investigated for the treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT Compare (A3921080) and OPT Retreatment (A3921111).

10 Oct 2013

Tel Aviv University researchers find chemicals in marijuana could help treat MS

Multiple sclerosis is an inflammatory disease in which the immune system attacks the nervous system. The result can be a wide range of debilitating motor, physical, and mental problems. No one knows why people get the disease or how to treat it.

8 Oct 2013

High-dose statins could have added benefit of reducing gum inflammation

The use of high-dose statins to lower cholesterol in heart disease patients appears to have the added benefit of reducing gum inflammation, according to research published in the Journal of the American College of Cardiology.

4 Oct 2013

New picture of interaction between nervous & immune systems could lead to novel therapies

A new picture of how the nervous system interacts with the immune system to cause the itch and inflammation associated with eczema, a chronic skin disease, could lead to new therapies for the condition, according to University of California, Berkeley, scientists.

4 Oct 2013

New classification criteria for systemic sclerosis published in ACR journal

New classification criteria for systemic sclerosis have just been published and are more sensitive than the 1980 criteria, enabling earlier identification and treatment of this disabling autoimmune disease.

3 Oct 2013

Dental caries show ‘unexpected’ relationship with head and neck cancer

People with dental caries have a reduced risk for developing head and neck squamous cell carcinoma, a large case-control study has found.

24 Sep 2013

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.

24 Sep 2013

ACR journals publish guide that provides new treatments for children with systemic JIA

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative.

24 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

Inflammatory Disease News and Research

BioLineRx obtains regulatory approval to initiate BL-7010 Phase 1/2 trial for celiac disease

Can-Fite BioPharma executes confidentiality agreements for commercialization of CF101 drug

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Researchers identify risk factors, protective medication for people living with lupus

Study: Headache is not a sign of lupus activity

Biomarker may predict poor pregnancy outcomes in lupus patients

Study reveals that Medicaid beneficiaries with lupus not following treatment plans

Children born to mothers with lupus have twice the risk of autism spectrum disorders

NHMRC awards over $6M for Griffith University research projects

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

New injection device to reduce fear and pain of injecting modern medicines

Pfizer reports positive results from two tofacitinib Phase 3 trials for chronic plaque psoriasis

Tel Aviv University researchers find chemicals in marijuana could help treat MS

High-dose statins could have added benefit of reducing gum inflammation

New picture of interaction between nervous & immune systems could lead to novel therapies

New classification criteria for systemic sclerosis published in ACR journal

Dental caries show ‘unexpected’ relationship with head and neck cancer

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

ACR journals publish guide that provides new treatments for children with systemic JIA

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Industry Focus eBook - Cell biology (5th edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News